ストックスクリーナーアプリを入手
16.07
2.81%
-0.472
前日終値:
$16.54
開ける：
$16.46
24時間の取引高:
190.67K
Relative Volume:
0.14
時価総額：
$812.53M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-4.3545
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
+10.10%
1か月 パフォーマンス:
+2.06%
6か月 パフォーマンス:
+3.31%
1年 パフォーマンス:
+83.71%
1日の値動き範囲:
$15.95
$16.56
1週間の範囲:
$14.22
$16.65
52週間の値動き範囲:
$8.49
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
16.07 | 836.04M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.40 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.13 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.55 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.91 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.33 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | 繰り返されました | Needham | Buy |
| 2026-01-06 | 繰り返されました | Needham | Buy |
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Does KalVista Pharmaceuticals (KALV) have the potential to rally 117.98% as Wall Street analysts expect? - MSN
Hereditary Angioedema Market Poised for Strong Growth, Valued - openPR.com
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Multicare and KalVista collaboration in Latin America - The Pharma Letter
Multicare, KalVista to expand oral HAE treatment in Latin America - Mexico Business News
Aug Macro: What analysts say about KalVista Pharmaceuticals Inc stockQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Recap Report: What chart patterns are forming on KalVista Pharmaceuticals IncWeekly Profit Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Can KalVista Pharmaceuticals Inc withstand a market correction2025 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-16 10:42:21 - baoquankhu1.vn
Aug Weekly: Can Zoetis Inc sustain its profitabilityOptions Play & Technical Entry and Exit Tips - baoquankhu1.vn
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - sharewise.com
Can KalVista Pharmaceuticals Inc stock sustain revenue growthQuarterly Earnings Report & Long-Term Growth Plans - Bộ Nội Vụ
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2%Time to Sell? - MarketBeat
KalVista reports $49M in 2025 Ekterly revenue, shares rise - msn.com
HAE treatment Ekterly hits $49M sales in months since July launch - Angioedema News
The Technical Signals Behind (KALV) That Institutions Follow - Stock Traders Daily
Analysts Expect Breakeven For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Before Long - 富途资讯
What is HC Wainwright's Forecast for KALV FY2030 Earnings? - MarketBeat
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales By Investing.com - Investing.com South Africa
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com Nigeria
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - Benzinga
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales - Investing.com Australia
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals (KALV) Receives Buy Rating with Increas - GuruFocus
Kalvista stock price target raised to $29 from $28 at Citizens on strong Ekterly launch - Investing.com Australia
KALV: Needham Raises Price Target to $35, Maintains Buy Rating | - GuruFocus
KalVista Stock Pre-Market (+14%) : Reports Strong EKTERLY Launch Revenue - Trefis
KalVista Pharmaceuticals stock rallies after hours on strong genetic disorder drug sales kickstart - MSN
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart - Stocktwits
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY By Investing.com - Investing.com South Africa
KalVista stock soars after strong Q4 revenue for oral HAE treatment EKTERLY - Investing.com Nigeria
KalVista reports $35 million Q4 revenue for oral HAE treatment EKTERLY - Investing.com
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - The Joplin Globe
PRN_FinancialWrapper - FinancialContent
KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Will KalVista Pharmaceuticals Inc. (4XC1) stock sustain bullish trend into 2025Weekly Gains Summary & Weekly Breakout Watchlists - Улправда
How KalVista Pharmaceuticals Inc. (4XC1) stock moves in volatile trading sessions - bollywoodhelpline.com
Aug Sectors: Is KalVista Pharmaceuticals Inc stock supported by innovation pipeline2025 Retail Activity & Technical Buy Zone Confirmation - Bộ Nội Vụ
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.06%
大文字化:
|
ボリューム (24 時間):